HealthcareServices

Edema Clinical Trials Market Size Forecast: Revenue and CAGR by 2029

November 21, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Market Value Is The Edema Clinical Trials Industry Expected To Reach By 2029, Starting From 2025 Levels?

The edema clinical trials market has seen robust growth over the past few years. It is anticipated to expand from $1.13 billion in 2024 to $1.23 billion in 2025, showing a compound annual growth rate (CAGR) of 8.9%. This historical growth can be attributed to several factors including the rising prevalence of edema conditions, an increasing burden of chronic diseases, greater healthcare awareness and improved diagnosis, a significant expansion of healthcare infrastructure, an aging global population, and increased funding from both public and private sources.

The edema clinical trials market is projected to experience robust expansion in the coming years. By 2029, its valuation is anticipated to reach $1.71 billion, exhibiting a compound annual growth rate (CAGR) of 8.6%. This forecasted growth stems from several factors, including an increasing demand for personalized medicine, a heightened focus on diversifying patient recruitment, a rise in decentralized and virtual clinical trials, the proliferation of government support programs, and increased investment from global pharmaceutical firms. Significant trends during this period are expected to encompass technological progress in remote monitoring, breakthroughs in digital biomarkers, the evolution of artificial intelligence analytics, improvements in three-dimensional imaging, intensive research and development in personalized therapies, and the incorporation of telemedicine into trials.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=28211&type=smp

What Are The Drivers Pushing New Developments In The Edema Clinical Trials Market?

A rise in lifestyle-related diseases is projected to boost the expansion of the edema clinical trials market in the future. These diseases are conditions stemming from everyday habits and decisions, such as a sedentary lifestyle, poor dietary choices, and substance abuse. The prevalence of lifestyle illnesses is on the rise, primarily due to poor eating habits, with the extensive intake of processed and calorie-dense foods leading to issues like obesity, diabetes, and cardiovascular conditions. Edema clinical trials aid in managing lifestyle-related diseases by creating and evaluating therapies aimed at resolving fluid accumulation associated with obesity, diabetes, and cardiovascular disorders. For example, in March 2024, data from the Office for Health Improvement & Disparities, a UK-based government department, revealed that from March 2022 to March 2023, there was a 22% increase in the proportion of individuals with type 1 diabetes receiving all eight recommended care processes, and a 21% increase for those with type 2 diabetes. Concurrently, the proportion reaching target HbA1c levels climbed to 37.9%, which was the highest figure ever recorded by the National Diabetes Audit (NDA). Consequently, the growing occurrence of lifestyle-related diseases is fueling the expansion of the edema clinical trials market.

What Are The Primary Types Of Segments Analyzed In The Edema Clinical Trials Market?

The edema clinical trials market covered in this report is segmented as

1) By Phase: Phase I, Phase II, Phase III, Phase IV

2) By Type: Peripheral Edema, Pulmonary Edema, Cerebral Edema, Nephrotic Syndrome Edema

3) By Study Design: Interventional, Observational, Expanded Access

4) By Participant: Pediatrics, Adults, Geriatrics

5) By End User: Pharmaceutical Companies, Research Institutions, Contract Research Organizations (CROs), Academic Research Centers

Subsegments:

1) By Phase I: Single Ascending Dose, Multiple Ascending Dose

2) By Phase II: Proof of Concept, Phase IIb Dose Optimization

3) By Phase III: Pivotal Efficacy Trials, Comparative Trials

4) By Phase IV: Post-Marketing Surveillance, Long-Term Safety Studies

How Are Emerging Market Trends Shaping The Edema Clinical Trials Industry Landscape?

Leading firms within the edema clinical trials market are concentrating on creating novel solutions, notably refillable ocular implants, to enhance the effectiveness of treatment and patient adherence in addressing chronic eye conditions linked to edema. This type of implant is a medical device placed in the eye designed to deliver medication continuously for prolonged durations, enabling regular drug refills without requiring the implant’s removal or replacement, thereby providing ongoing treatment for conditions such as macular edema. As an illustration, in February 2025, Roche Holding AG, a pharmaceutical firm based in Switzerland, gained FDA approval for Susvimo, recognized as the inaugural and sole continuous delivery therapy for diabetic macular edema (DME) and diabetic retinopathy (DR), which are significant contributors to diabetes-induced blindness. This offers a substitute for numerous eye injections by requiring considerably fewer yearly treatments. This groundbreaking approval signifies a notable progression in ophthalmic treatment, given that Susvimo’s implantable delivery mechanism aids in boosting patient compliance and lessening the demands of treatment, potentially leading to improved long-term results for those affected by these persistent ocular conditions.

Who Are The Primary Competitors In The Global Edema Clinical Trials Market?

Major companies operating in the edema clinical trials market are Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis International AG, CSL Limited, Regeneron Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Genentech Inc., Ionis Pharmaceuticals Inc., ANI Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., Tactile Medical, REGENXBIO Inc., Koya Medical Inc., KalVista Pharmaceuticals Inc., Kodiak Sciences Inc., Pharvaris B.V., Oxurion NV, Outlook Therapeutics Inc., Adverum Biotechnologies Inc., Oculis Holding AG.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/edema-clinical-trials-global-market-report

Which Geographies Are Emerging As Strong Markets For The Edema Clinical Trials Industry?

North America was the largest region in the edema clinical trials market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in edema clinical trials report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Request A Customized Version Of The Edema Clinical Trials Market Report:

https://www.thebusinessresearchcompany.com/customise?id=28211&type=smp

Browse Through More Reports Similar to the Global Edema Clinical Trials Market 2025, By The Business Research Company

Ecoa Esource And Clinical Trials Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/ecoa-esource-and-clinical-trials-global-market-report

Cardiovascular Clinical Trials Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cardiovascular-clinical-trials-global-market-report

Healthcare Edi Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/healthcare-edi-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795